217 related articles for article (PubMed ID: 21341675)
1. Structure-based design of potent and selective 3-phosphoinositide-dependent kinase-1 (PDK1) inhibitors.
Medina JR; Becker CJ; Blackledge CW; Duquenne C; Feng Y; Grant SW; Heerding D; Li WH; Miller WH; Romeril SP; Scherzer D; Shu A; Bobko MA; Chadderton AR; Dumble M; Gardiner CM; Gilbert S; Liu Q; Rabindran SK; Sudakin V; Xiang H; Brady PG; Campobasso N; Ward P; Axten JM
J Med Chem; 2011 Mar; 54(6):1871-95. PubMed ID: 21341675
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and SAR of novel 4-morpholinopyrrolopyrimidine derivatives as potent phosphatidylinositol 3-kinase inhibitors.
Chen Z; Venkatesan AM; Dehnhardt CM; Ayral-Kaloustian S; Brooijmans N; Mallon R; Feldberg L; Hollander I; Lucas J; Yu K; Kong F; Mansour TS
J Med Chem; 2010 Apr; 53(8):3169-82. PubMed ID: 20334367
[TBL] [Abstract][Full Text] [Related]
3. Discovery of novel, potent, and selective inhibitors of 3-phosphoinositide-dependent kinase (PDK1).
Murphy ST; Alton G; Bailey S; Baxi SM; Burke BJ; Chappie TA; Ermolieff J; Ferre R; Greasley S; Hickey M; Humphrey J; Kablaoui N; Kath J; Kazmirski S; Kraus M; Kupchinsky S; Li J; Lingardo L; Marx MA; Richter D; Tanis SP; Tran K; Vernier W; Xie Z; Yin MJ; Yu XH
J Med Chem; 2011 Dec; 54(24):8490-500. PubMed ID: 22040023
[TBL] [Abstract][Full Text] [Related]
4. PDK1 Inhibitor GSK-470 Exhibits Potent Anticancer Activity in a Pheochromocytoma PC12 Cell Tumor Model via Akt/mTOR Pathway.
Zhang X; Zhong S
Anticancer Agents Med Chem; 2020; 20(7):828-833. PubMed ID: 32188393
[TBL] [Abstract][Full Text] [Related]
5. The discovery of PLK4 inhibitors: (E)-3-((1H-Indazol-6-yl)methylene)indolin-2-ones as novel antiproliferative agents.
Laufer R; Forrest B; Li SW; Liu Y; Sampson P; Edwards L; Lang Y; Awrey DE; Mao G; Plotnikova O; Leung G; Hodgson R; Beletskaya I; Mason JM; Luo X; Wei X; Yao Y; Feher M; Ban F; Kiarash R; Green E; Mak TW; Pan G; Pauls HW
J Med Chem; 2013 Aug; 56(15):6069-87. PubMed ID: 23829549
[TBL] [Abstract][Full Text] [Related]
6. Potent, selective, and orally bioavailable inhibitors of mammalian target of rapamycin (mTOR) kinase based on a quaternary substituted dihydrofuropyrimidine.
Cohen F; Bergeron P; Blackwood E; Bowman KK; Chen H; Dipasquale AG; Epler JA; Koehler MF; Lau K; Lewis C; Liu L; Ly CQ; Malek S; Nonomiya J; Ortwine DF; Pei Z; Robarge KD; Sideris S; Trinh L; Truong T; Wu J; Zhao X; Lyssikatos JP
J Med Chem; 2011 May; 54(9):3426-35. PubMed ID: 21495671
[TBL] [Abstract][Full Text] [Related]
7. ATP-competitive inhibitors of the mammalian target of rapamycin: design and synthesis of highly potent and selective pyrazolopyrimidines.
Zask A; Verheijen JC; Curran K; Kaplan J; Richard DJ; Nowak P; Malwitz DJ; Brooijmans N; Bard J; Svenson K; Lucas J; Toral-Barza L; Zhang WG; Hollander I; Gibbons JJ; Abraham RT; Ayral-Kaloustian S; Mansour TS; Yu K
J Med Chem; 2009 Aug; 52(16):5013-6. PubMed ID: 19645448
[TBL] [Abstract][Full Text] [Related]
8. Cdc7 kinase inhibitors: 5-heteroaryl-3-carboxamido-2-aryl pyrroles as potential antitumor agents. 1. Lead finding.
Menichincheri M; Albanese C; Alli C; Ballinari D; Bargiotti A; Caldarelli M; Ciavolella A; Cirla A; Colombo M; Colotta F; Croci V; D'Alessio R; D'Anello M; Ermoli A; Fiorentini F; Forte B; Galvani A; Giordano P; Isacchi A; Martina K; Molinari A; Moll JK; Montagnoli A; Orsini P; Orzi F; Pesenti E; Pillan A; Roletto F; Scolaro A; Tatò M; Tibolla M; Valsasina B; Varasi M; Vianello P; Volpi D; Santocanale C; Vanotti E
J Med Chem; 2010 Oct; 53(20):7296-315. PubMed ID: 20873740
[TBL] [Abstract][Full Text] [Related]
9. Discovery and optimization of a series of benzothiazole phosphoinositide 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) dual inhibitors.
D'Angelo ND; Kim TS; Andrews K; Booker SK; Caenepeel S; Chen K; D'Amico D; Freeman D; Jiang J; Liu L; McCarter JD; San Miguel T; Mullady EL; Schrag M; Subramanian R; Tang J; Wahl RC; Wang L; Whittington DA; Wu T; Xi N; Xu Y; Yakowec P; Yang K; Zalameda LP; Zhang N; Hughes P; Norman MH
J Med Chem; 2011 Mar; 54(6):1789-811. PubMed ID: 21332118
[TBL] [Abstract][Full Text] [Related]
10. Rapid development of piperidine carboxamides as potent and selective anaplastic lymphoma kinase inhibitors.
Bryan MC; Whittington DA; Doherty EM; Falsey JR; Cheng AC; Emkey R; Brake RL; Lewis RT
J Med Chem; 2012 Feb; 55(4):1698-705. PubMed ID: 22263917
[TBL] [Abstract][Full Text] [Related]
11. Identification and optimisation of novel and selective small molecular weight kinase inhibitors of mTOR.
Menear KA; Gomez S; Malagu K; Bailey C; Blackburn K; Cockcroft XL; Ewen S; Fundo A; Le Gall A; Hermann G; Sebastian L; Sunose M; Presnot T; Torode E; Hickson I; Martin NM; Smith GC; Pike KG
Bioorg Med Chem Lett; 2009 Oct; 19(20):5898-901. PubMed ID: 19733066
[TBL] [Abstract][Full Text] [Related]
12. Discovery of a potent, selective, and orally bioavailable pyridinyl-pyrimidine phthalazine aurora kinase inhibitor.
Cee VJ; Schenkel LB; Hodous BL; Deak HL; Nguyen HN; Olivieri PR; Romero K; Bak A; Be X; Bellon S; Bush TL; Cheng AC; Chung G; Coats S; Eden PM; Hanestad K; Gallant PL; Gu Y; Huang X; Kendall RL; Lin MH; Morrison MJ; Patel VF; Radinsky R; Rose PE; Ross S; Sun JR; Tang J; Zhao H; Payton M; Geuns-Meyer SD
J Med Chem; 2010 Sep; 53(17):6368-77. PubMed ID: 20684549
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis, and biological evaluation of pyrazolopyrimidine-sulfonamides as potent multiple-mitotic kinase (MMK) inhibitors (part I).
Zhang L; Fan J; Chong JH; Cesena A; Tam BY; Gilson C; Boykin C; Wang D; Aivazian D; Marcotte D; Xiao G; Le Brazidec JY; Piao J; Lundgren K; Hong K; Vu K; Nguyen K; Gan LS; Silvian L; Ling L; Teng M; Reff M; Takeda N; Timple N; Wang Q; Morena R; Khan S; Zhao S; Li T; Lee WC; Taveras AG; Chao J
Bioorg Med Chem Lett; 2011 Sep; 21(18):5633-7. PubMed ID: 21798738
[TBL] [Abstract][Full Text] [Related]
14. PDK1 and PKB/Akt: ideal targets for development of new strategies to structure-based drug design.
Harris TK
IUBMB Life; 2003 Mar; 55(3):117-26. PubMed ID: 12822887
[TBL] [Abstract][Full Text] [Related]
15. Lead optimization of N-3-substituted 7-morpholinotriazolopyrimidines as dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitors: discovery of PKI-402.
Dehnhardt CM; Venkatesan AM; Delos Santos E; Chen Z; Santos O; Ayral-Kaloustian S; Brooijmans N; Mallon R; Hollander I; Feldberg L; Lucas J; Chaudhary I; Yu K; Gibbons J; Abraham R; Mansour TS
J Med Chem; 2010 Jan; 53(2):798-810. PubMed ID: 19968288
[TBL] [Abstract][Full Text] [Related]
16. Selective benzopyranone and pyrimido[2,1-a]isoquinolin-4-one inhibitors of DNA-dependent protein kinase: synthesis, structure-activity studies, and radiosensitization of a human tumor cell line in vitro.
Griffin RJ; Fontana G; Golding BT; Guiard S; Hardcastle IR; Leahy JJ; Martin N; Richardson C; Rigoreau L; Stockley M; Smith GC
J Med Chem; 2005 Jan; 48(2):569-85. PubMed ID: 15658870
[TBL] [Abstract][Full Text] [Related]
17. For a PDK1 inhibitor, the substrate matters.
Knight ZA
Biochem J; 2011 Jan; 433(2):e1-2. PubMed ID: 21175429
[TBL] [Abstract][Full Text] [Related]
18. The discovery and optimisation of pyrido[2,3-d]pyrimidine-2,4-diamines as potent and selective inhibitors of mTOR kinase.
Malagu K; Duggan H; Menear K; Hummersone M; Gomez S; Bailey C; Edwards P; Drzewiecki J; Leroux F; Quesada MJ; Hermann G; Maine S; Molyneaux CA; Le Gall A; Pullen J; Hickson I; Smith L; Maguire S; Martin N; Smith G; Pass M
Bioorg Med Chem Lett; 2009 Oct; 19(20):5950-3. PubMed ID: 19762236
[TBL] [Abstract][Full Text] [Related]
19. Indazolylpyrazolopyrimidine as highly potent B-Raf inhibitors with in vivo activity.
Wang X; Berger DM; Salaski EJ; Torres N; Dutia M; Hanna C; Hu Y; Levin JI; Powell D; Wojciechowicz D; Collins K; Frommer E; Lucas J
J Med Chem; 2010 Nov; 53(21):7874-8. PubMed ID: 20961062
[TBL] [Abstract][Full Text] [Related]
20. 1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazoles: identification of a potent Aurora kinase inhibitor with a favorable antitumor kinase inhibition profile.
Fancelli D; Moll J; Varasi M; Bravo R; Artico R; Berta D; Bindi S; Cameron A; Candiani I; Cappella P; Carpinelli P; Croci W; Forte B; Giorgini ML; Klapwijk J; Marsiglio A; Pesenti E; Rocchetti M; Roletto F; Severino D; Soncini C; Storici P; Tonani R; Zugnoni P; Vianello P
J Med Chem; 2006 Nov; 49(24):7247-51. PubMed ID: 17125279
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
